

# Molecular subclassification of vulvar squamous cell carcinoma: prognostic significance of a novel surgical technique

International Journal of Gynecological Cancer

32, 977-985

DOI: 10.1136/ijgc-2021-003251

Citation Report

#	ARTICLE	IF	CITATIONS
1	Significance of p53 and presence of differentiated vulvar intra-epithelial neoplasia (dVIN) at resection margin in early stage human papillomavirus-independent vulvar squamous cell carcinoma. International Journal of Gynecological Cancer, 2022, 32, 1229-1235.	2.5	3
2	Mass Spectrometry Proteomic Analysis of Four p53 Patterns in Differentiated Vulvar Intraepithelial Neoplasia. Journal of Lower Genital Tract Disease, 0, Publish Ahead of Print, .	1.9	0
3	Reply to Comment on HPV-independent, p53-Wild-type Vulvar Intraepithelial Neoplasia: A Review of Nomenclature and the Journey to Characterize Acanthotic Precursor Lesions of the Vulva. Modern Pathology, 2023, 36, 100053.	5.5	5
4	Classification of Vulvar Squamous Cell Carcinoma and Precursor Lesions by p16 and p53 Immunohistochemistry: Considerations, Caveats, and an Algorithmic Approach. Modern Pathology, 2023, 36, 100145.	5.5	8
5	Human papillomavirus and p53 status define three types of vulvar squamous cell carcinomas with distinct clinical, pathological, and prognostic features. Histopathology, 2023, 83, 17-30.	2.9	5
6	Coexpression of p53 and p16 in Vulvar Squamous Neoplasia. Modern Pathology, 2023, 36, 100319.	5.5	0
7	GATA3 Expression in HPV-associated and HPV-independent Vulvar Squamous Cell Carcinomas: Patterns of Expression and Prognostic Significance. Applied Immunohistochemistry and Molecular Morphology, 0, , .	1.2	0
8	Androgen Insensitivity Syndrome with Bilateral Gonadal Sertoli Cell Lesions, Sertoliâ€“Leydig Cell Tumor, and Paratesticular Leiomyoma: A Case Report and First Systematic Literature Review. Journal of Clinical Medicine, 2024, 13, 929.	2.4	0
9	High concordance of molecular subtyping between pre-surgical biopsy and surgical resection specimen (matched-pair analysis) in patients with vulvar squamous cell carcinoma using p16- and p53-immunostaining. Gynecologic Oncology, 2024, 185, 17-24.	1.4	0